{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:35:46Z","timestamp":1793298946922,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euf.2026.06.013","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:37:56Z","timestamp":1782272276000},"page":"847-849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management?"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2123-145X","authenticated-orcid":false,"given":"Jean-Mathieu","family":"Beauregard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Pouliot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.06.013_b0005","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.06.013_b0010","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2026.06.013_b0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.euf.2026.06.013_b0020","doi-asserted-by":"crossref","first-page":"S1630","DOI":"10.1016\/j.annonc.2025.09.105","article-title":"LBA89 A randomized phase II study of 177Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21","volume":"36","author":"Chi","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2026.06.013_b0025","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2026.06.013_b0030","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.annonc.2025.07.003","article-title":"Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Fizazi","year":"2025","journal-title":"Ann Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.euf.2026.06.013_b0035","doi-asserted-by":"crossref","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2308","article-title":"LBA65 Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH)","volume":"35","author":"Sartor","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2026.06.013_b0040","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1002\/cam4.5401","article-title":"A population-based study of factors associated with systemic treatment in advanced prostate cancer decedents","volume":"12","author":"Leigh","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.euf.2026.06.013_b0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.9433","article-title":"Treatment patterns and survival among veterans with de novo metastatic hormone-sensitive prostate cancer","volume":"8","author":"Schoen","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euf.2026.06.013_b0050","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926001094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926001094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:58:36Z","timestamp":1793296716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926001094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2405456926001094"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.06.013","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management?","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}